(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 18.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.
Lyell Immunopharma's earnings in 2025 is -$342,994,000.On average, 4 Wall Street analysts forecast LYEL's earnings for 2025 to be -$208,874,424, with the lowest LYEL earnings forecast at -$239,135,383, and the highest LYEL earnings forecast at -$171,232,743. On average, 3 Wall Street analysts forecast LYEL's earnings for 2026 to be -$199,781,375, with the lowest LYEL earnings forecast at -$253,896,826, and the highest LYEL earnings forecast at -$126,948,413.
In 2027, LYEL is forecast to generate -$259,801,404 in earnings, with the lowest earnings forecast at -$259,801,404 and the highest earnings forecast at -$259,801,404.